Montreal Cognitive Assessment Index Following MRI Guided Focused Ultrasound Thalamotomy

Montreal Cognitive Assessment Index Following MRI Guided Focused Ultrasound

We assessed Montreal Cognitive Assessment scores before and after MRI guided focused ultrasound thalamotomy for tremor in order to identify if there are changes in cognitive function following treatment.

Study Overview

• Status: Completed
• Conditions: Essential Tremor
• Intervention / Treatment: Other: Data collection

Detailed Description

All patients who underwent MRI guided focused ultrasound thalamotomy underwent cognitive assessment by Montreal Cognitive Assessment. We calculated the scores before and after treatment and compared the results.

• Study Type: Observational
• Enrollment (Actual): 142

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients that underwent MRI guided focused ultrasound thalamotomy and suffered from Essential tremor.

Description

Inclusion Criteria:

• Patients that underwent MRI guided focused ultrasound thalamotomy and suffered from Essential tremor.

Exclusion Criteria:

• Patients that did not undergo MRI guided focused ultrasound thalamotomy
• Patinets that did not suffer from Essential tremor.
• Patients that underwent MRI guided focused ultrasound for areas other then a thalamus
• Patients tat underwent bilateral thalamothomy

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Montreal Cognitive Assessment	Cognitive assessessment with higher score indicating better cognitive state	baselin, preprocedure, 6 months and 1 year

Collaborators and Investigators

• Sponsor: Rambam Health Care Campus
• Investigators: Study Director: Inna Senderova, Rambam Health Care Campus

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2013
• Primary Completion (Actual): June 1, 2024
• Study Completion (Actual): June 1, 2024

Study Registration Dates

• First Submitted: April 16, 2025
• First Submitted That Met QC Criteria: April 16, 2025
• First Posted (Actual): April 23, 2025

Study Record Updates

• Last Update Posted (Actual): April 23, 2025
• Last Update Submitted That Met QC Criteria: April 16, 2025
• Last Verified: April 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Essential Tremor
• Other Study ID Numbers: RMB0404-17

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No